Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Pediatr Pulmonol. 2011 Nov;46(11):1108-13. doi: 10.1002/ppul.21480. Epub 2011 Aug 3.
Critically ill children treated with extracorporeal membrane oxygenation (ECMO) support frequently have respiratory complications amenable to evaluation by flexible bronchoscopy (FB). The safety and efficacy of FB in this setting has not been well described in children.
Retrospective analysis of 153 FBs in 79 children treated with ECMO at a single institution from 2000 to 2008. Demographic data, clinical findings, and complications were obtained. Chest radiographs reports were evaluated prior to and following FB. Physiologic variables were compared prior to and following FB.
Seventy-nine patients underwent FB on ECMO [58 veno-venous (VV) and 21 veno-arterial (VA) ECMO], with 153 total FBs performed. Indications for FB included clearance of tenacious airway secretions (n = 118, 77%), or evaluation of suspected secondary infections with bronchoalveolar lavage (n = 26, 17%). Two patients also had surfactant instillation following secretion removal. FB was performed a median 5 days following cannulation for ECMO (range 2-14 days). Most common findings included thick secretions (n = 77, 50.3%), mucoid secretions (n = 15, 9.8%), and mucopurulent secretions (n = 28, 18.3%). No deterioration in radiographic lung findings was described post-FB. FB was not associated with any significant change in heart rate, systemic blood pressure, or temperature. No significant changes in ECMO pump flow rate or sweep gas flow was seen during or after FB. Cannula dislodgement, inadvertent extubation, fever, pneumothorax, or intraprocedural hypoxemia was not reported. Fifty-three FBs (35%) resulted in blood-tinged secretions from the endotracheal tube post-FB, which resolved spontaneously. Three patients received high frequency oscillatory ventilation (HFOV) following FB in association with mild hemorrhage.
FB is a well-tolerated and safe procedure in critically ill pediatric patients on ECMO. FB may have a diagnostic as well as therapeutic benefit in such patients.
接受体外膜肺氧合(ECMO)支持治疗的危重症儿童常发生肺部并发症,可通过纤维支气管镜(FB)进行评估。在这种情况下,FB 在儿童中的安全性和疗效尚未得到很好的描述。
对 2000 年至 2008 年期间在一家机构接受 ECMO 治疗的 79 名儿童的 153 次 FB 进行回顾性分析。获取人口统计学数据、临床发现和并发症。在进行 FB 之前和之后评估胸部 X 线报告。比较 FB 前后的生理变量。
79 名患者在 ECMO 上进行了 FB[58 例静脉-静脉(VV)和 21 例静脉-动脉(VA)ECMO],共进行了 153 次 FB。FB 的指征包括清除粘稠的气道分泌物(n=118,77%)或通过支气管肺泡灌洗评估疑似继发感染(n=26,17%)。两名患者在清除分泌物后还进行了表面活性剂注入。FB 在 ECMO 置管后中位数 5 天进行(范围 2-14 天)。最常见的发现包括厚分泌物(n=77,50.3%)、黏液分泌物(n=15,9.8%)和黏液脓性分泌物(n=28,18.3%)。FB 后没有描述影像学肺部发现恶化。FB 与心率、全身血压或体温无显著变化相关。在 FB 期间或之后,没有观察到 ECMO 泵流量或吹扫气体流量的显著变化。没有报告导管移位、意外拔管、发热、气胸或术中低氧血症。53 次 FB(35%)在 FB 后导致气管内导管中出现带血分泌物,这些分泌物自行消退。三名患者在 FB 后接受高频振荡通气(HFOV)治疗,同时伴有轻度出血。
FB 是 ECMO 治疗危重症儿科患者的一种耐受良好且安全的程序。FB 可能对这类患者具有诊断和治疗益处。